Search Within

Aaron David Goldberg

Formats
  1. Meeting Abstract (61)
  2. Journal Article (30)
  3. Research Letter (6)
  4. Correspondence (3)
  5. Editorial (3)
  6. Review (2)
  7. Book Section (1)
Groups
  1. Adult Leukemia (106)
  2. Center for Hematologic Malignancies (106)
  3. Department of Medicine (106)
  4. Hematologic Malignancies, Division of (106)
  5. Weinberg Fellows (106)
  6. Hematology-Oncology Fellows (48)

More Groups

People
  1. Martin Tallman (46)
  2. Eytan Stein (38)
  3. Christopher Famulare (36)
  4. Ross Levine (20)
  5. Jan Bewersdorf (19)
  6. Andriy Derkach (18)

More People

Years
  1. 2025 (2)
  2. 2024 (11)
  3. 2023 (20)
  4. 2022 (15)
  5. 2021 (15)
  6. 2020 (15)

More Years

Publications
  1. Blood (55)
  2. Leukemia and Lymphoma (8)
  3. American Journal of Hematology (6)
  4. Blood Advances (5)
  5. Journal of Clinical Oncology (5)
  6. Haematologica (4)

More Publications

Publishers
  1. American Society of Hematology (60)
  2. Taylor & Francis Group (8)
  3. American Society of Clinical Oncology (6)
  4. John Wiley & Sons, Inc. (5)
  5. Ferrata Storti Foundation (4)
  6. Nature Publishing Group (4)

More Publishers

Results (106)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
    Journal Article

    Bewersdorf, J. P.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia
    Journal Article

    Badar, T.; Litzow, M. R.; Shallis, R. M.; Patel, A.; Saliba, A. N.; Burkart, M.; Bewersdorf, J. P.; Stahl, M.; De Camargo Correia, G. S.; Guru Murthy, G. S.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
    Journal Article

    Stahl, M.; Derkach, A.; Farnoud, N.; Bewersdorf, J. P.; Robinson, T.; Famulare, C.; Cho, C.; Devlin, S.; Menghrajani, K.; Patel, M. A.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Outcomes based on sequential use of venetoclax based therapy and targeted therapy in acute myeloid leukemia (AML)
    Meeting Abstract

    Stahl, M.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Comparison of patients with newly diagnosed (ND) acute myeloid leukemia (AML) treated with venetoclax and hypomethylating agents vs other therapies by TP53 and IDH1/2 mutation: Results from the AML Real World Evidence (ARC) Initiative
    Meeting Abstract

    Wolach, O.; Garcia, J. S.; Desai, P.; Vachhani, P.; Zeidner, J. F.; Abedin, S.; Sweet, K.; Lai, C.; Moshe, Y.; Pollyea, D. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Quantitative cytogenetic analysis with karyoParser allows for more precise identification of disease biology, clonal evolution, and etiology of relapse in acute myeloid leukemia
    Meeting Abstract

    Dilip, D.; Derkach, A.; Menghrajani, K.; Goldberg, A. D.; May, H.; Klimek, V. M.; Galera, P. K.; Xiao, W.; Zhang, Y.; Elemento, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 1a/b dose escalation study of the FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Goldberg, A. D.; Ohanian, M.; Koller, P. B.; Cherry, M.; Altman, J. K.; Tomlinson, B.; Chandhok, N. S.; Haney, D. N.; Hu, J.; Sinha, R. K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Intensive therapy for NPM1 mutant AML patients: Negative impact of FLT3-ITD(high)but not FLT3-ITD(low) and FLT3TKD and role of transplant in patients over 60 years of age
    Meeting Abstract

    Winer, E. S.; Flamand, Y.; Shallis, R. M.; Stempel, J. M.; Goldberg, A. D.; Stahl, M. F.; Patel, A. A.; Duvall, A. S.; Abaza, Y.; Oh, T. S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with TP53-mutated AML after first relapse or with primary refractory disease: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND)
    Meeting Abstract

    Badar, T.; Atallah, E. L.; Saliba, A. N.; Shallis, R. M.; Stahl, M. F.; Bewersdorf, J. P.; Correia, G. S. D.; Patel, A. A.; Abaza, Y.; Murthy, G. S. G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia
    Meeting Abstract

    Robinson, T.; Bowman, R. L.; Persaud, S.; Liu, Y.; Gao, Q.; Zhang, J. P.; Sun, X.; Sciambi, A.; Llanso, A.; Famulare, C.; more...
    Blood (2022)

    Fulltext@MSK | Save